All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 158 of 206 pages ‹ First < 156 157 158 159 160 > Last ›
HSL1935
Simmer WS.
Just what the doctor ordered: avoiding kickback pitfalls with prescription drugs.
Manag Care Interface 2002 Jan;15:(1):90-2
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11828611
HSL1978
National Health Council 2002 Jan;
http://www.nationalhealthcouncil.org/advocacy/DTC_paper.pdf
HSL25
Saver JL, Kidwell CS, Starkman S.
Commentary: thrombolysis in stroke: it works!
BMJ 2002;324:727-729
http://bmj.bmjjournals.com/cgi/content/full/324/7339/723
HSL26
Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM.
Promotion of prescription drugs to consumers
N Engl J Med 2002;346:498-505
http://content.nejm.org/cgi/content/abstract/346/7/498
HSL27
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, et al.
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey
BMJ 2002;324:278-279
http://bmj.bmjjournals.com/cgi/content/full/324/7332/278
HSL29
Coyle SL.
Physician-industry relations. Part 2: organizational issues
Ann Intern Med 2002;136:403-406
http://www.annals.org/cgi/reprint/136/5/403.pdf
HSL30
Coyle SL.
Physician-industry relations. Part 1: individual physicians
Ann Intern Med 2002;136:396-401
http://www.annals.org/cgi/reprint/136/5/396.pdf
HSL31
Choudhry NK, Stelfox HT, Detsky AS
Relationships between authors of clinical practice guidelines and the pharmaceutical industry
JAMA 2002;287:612-617
http://jama.ama-assn.org/cgi/content/full/287/5/612
HSL1654
Errett B.
What does it do? Um ... ask your doctor
National Post Date uncertain 2002
HSL1916
Warlow C.
Commentary: who pays the guideline writers
BMJ 2002;324:726-727
HSL1918
Vlasov VV.
[Emerging problems of medical ethics in Russia: medical practice and research]
Kardiologiia. 2002;42(5):81-4. 2002;42:(5):81-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12494154&query_hl=7
HSL1926
Syrycki M.
[Adaptation possibility of chosen aspects of pharmaceutical marketing for realization of promotion in health care]
Wiad Lek. 2002;55:(Suppl 1):482-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15002289
HSL1960
Saumande P.
[About "Almanach de la Pharmacie Brunot", pharmaceutical advertising in "Limousin" at the beginning of the XXth century]
Rev Hist Pharm (Paris). 2002;50:(335):451-60
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12521046&query_hl=2
HSL1972
Pavenik N.
Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Rand J Econ 2002 Aut;33:(3):469-87
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12585303
HSL1977
Neubauer A.
[Consequences of the German anticorruption law for sponsorship at university hospitals].
Wien Med Wochenschr 2002;152:(9-10):246-8
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1563-258X.2002.02038.x
HSL2027
Menon AM, Deshpande AD, Perri M 3rd,
inkhan M.
Trut in on ine precriptio drug iformation among internet users: the impact on information search behavir after exposur to dirct-to-cnsumer dvertis ng.
Helth Mark Q 2002;20:(1):17-35
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?md=Retr eve&db= ubmed&dpt=Abstact&lis_uids=1749596
HSL2098
Shakir SA, Layton D.
Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
Drug Saf 2002;25:(6):467-71
HSL2134
De Latt, Windmeijer F, Douven R.
How does pharmaceutical marketing influence doctors' prescribing behaviour?
The Hague: CPB Netherlands Bureau for Economic Policy Analysis 2002
http://www.cpb.nl/nl/pub/bijzonder/38
HSL2147
Families USA.
Profiting from pain: where prescription drug dollars go. Families USA Publication No. 02- 105.
Washington, DC: Families USA 2002 07
http://www.familiesusa.org/site/DocServer/PPreport.pdf?docID=249
HSL2148
WHO Department of Essential Drugs & Medicines Policy
Drug Promotion Database
: WHO Department of Essential Drugs & Medicines Policy 2002
http://www.drugpromo.info/
HSL2200
Marinozzi S.
[Images of anti-luetic therapeutic systems and drugs].
Med Secoli. 2002;14:(2):529-50
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14509998
HSL2202
Lyles A.
Direct marketing of pharmaceuticals to consumers.
Annu Rev Public Health 2002;23:73-91:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11910055
HSL2244
Lefebvre T.
[Archeology of the radio pharmaceutical advertisement].
Rev Hist Pharm (Paris). 2002;50:(336):647-64
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12731488
HSL2254
Kind M.
[Physicians--victims or promoters of corruption?].
Wien Med Wochenschr. 2002;152:(9-10):249-52
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12094402
HSL2255
Kemper DW, Mettler M.
A consumer-empowered response to direct-to-consumer advertising of prescription drugs.
Manag Care Q 2002 Spring;10:(2):52-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12148483
HSL2446
Jedrey CM, Chaurette KA, Winn LB.
Pharmaceutical company-sponsored disease management programs.
Manag Care Q 2002 Win;10:(1):56-60
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12476660http://
HSL2448
Isidor JM, Kaltman SP.
Fast track to disaster? Considerations raised by the current recruitment techniques for clinical research subjects
J Biolaw Bus 2002;5:(3):46-7
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12816118
HSL2450
Health Action International.
The Erice Statement on drug advertising to consumers
2002;
http://www.haiweb.org/campaign/DTCA/EriceStatement2002.doc
HSL2453
Hosch H.
[Research support and the pharmaceutical industry in Germany.]
Wien Med Wochenschr. 2002;152:(9-10):238-40
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12094398
HSL2454
Hoogenberg K, van der Tuin J.
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Ned Tijdschr Geneeskd. 2002 November 2;146:(44):2099-100
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12448967
HSL2457
Hochhauser M.
Which prescription for the illegible and unreadable DTC (direct-to-consumer) brief summary--major surgery or euthanasia?
Manag Care Q 2002 Sum;10:(3):6-10
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12476659
HSL2458
Hirsch LJ.
Conflicts of interest in drug development: the practices of Merck & Co., Inc
Sci Eng Ethics 2002 July;8:(3):429-42
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12353373
HSL2460
Healy DI.
Conflicting interests in Toronto: anatomy of a controversy at the interface of academia and industry.
Perspect Biol Med 2002 Spr;45:(2):250-63
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11919383
HSL2462
Graber MA, Weckmann M.
Pharmaceutical company internet sites as sources of information about antidepressant medications.
CNS Drugs 2002;16:(6):419-23
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12027787
HSL2463
Golden GA, Parochka JN, Overstreet KM.
Medical education and communication companies: an updated in-depth profile.
J Contin Educ Health Prof 2002 Win;22:(1):55-62
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12004641
HSL2467
Findlay S.
Do ads really drive pharmaceutical sales? The true effects of DTC advertising remain a mystery
Mark Health Serv. 2002 Spr;22:(1):20-25
HSL2487
Carter T.
What can Johnson & Johnson do to remain a giant in the health care industry?
J Hosp Mark Public Relations 2002;14:(1):93-103
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12569997
HSL2488
Calfee JE.
The role of marketing in pharmaceutical research and development.
Pharmacoeconomics 2002;20:(15 Supplement 3):77-85
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12457428
HSL2493
Bojunga G.
[Is research in Germany up for sale?
Results of a study of Transparency International Germany]Wien Med Wochenschr 2002;152:(9-10):244-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12094400
HSL2494
Bode UH, Geisler EP.
[Medical ethics as output of economically motivated industrial objectives].
Wien Med Wochenschr. 2002;152:(13-14):309-12
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12168510
HSL2498
Baird PA.
Identification of genetic susceptibility to common diseases: the case for regulation.
Perspect Biol Med 2002 Fal;45:(4):516-28
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12388884
HSL2500
Allen AJ, Michelson D.
Drug development process for a product with a primary pediatric indication.
J Clin Psychiatry 2002;63:44-9
http://www.psychiatrist.com/pcc/pccpdf/v04s04/v63s1207.pdf
HSL3698
Innvaer S, Vist G, Trommald M, Oxman A.
Health policy-makers’ perceptions of their use of evidence: a systematic review.
J Health Ser Res Policy. 2002;4:239–244
HSL3702
Coney S.
Direct-to-consumer advertising of prescription pharmaceuticals: a consumer perspective from New Zealand.
J Public Policy Market. 2002;21:213–223.
HSL3814
Is Yasmin a "truly different" pill?
Drug Ther Bull 2002;40:(8):57-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12216337
HSL4519
O'Keefe DJ.
Persuasion: Theory & Research 2nd Edn.
Thousand Oaks: Sage 2002
HSL4581
Kamm MA.
Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Eur J Surg Suppl 2002;(587):10-5
HSL4822
Ghosh S.
Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Fla J Int Law 2002 Spr;14:(2):217-60
HSL4823
Nagan WP.
International intellectual property, access to health care, and human rights: South Africa v. United States.
Fla J Int Law 2002 Spr;14:(2):155-91
HSL5662
Nakamura L.
Pious traders in medicine: a German pharmaceutical network in eighteenth-century North America. [Review of: Wilson, R. Pious traders in medicine: a German pharmaceutical network in eighteenth-century North America. University Park, Pa.: Penn State Pr., 2000]
J South Hist. 2002;68:(3):677-8
HSL7458
Palumbo FB, Mullins CD.
The Development of Direct-to-Consumer Prescription Drug Advertising Regulation
Food and Drug Law Journal 2002;57:(3):423-443
http://www.kff.org/rxdrugs/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=14372
HSL7625
Lexchin J.
Should doctors be prescribing new drugs?
International Journal of Risk and Safety in Medicine 2002;15:(3-4):213-222
HSL7628
Lawrence LW.
A study of consumer recall of prescription medication advertisements
Journal of Pharmaceutical Marketing and Management 2002;15:(1):52-58
HSL7629
Spiller LD, Wymer WW.
Physicians' responses to marketing strategies of pharmaceutical companies
Journal of Pharmaceutical Marketing and Management 2002;15:(1):15-30
HSL7640
Mossialos E, Mrazek MF.
Data needed for developing and monitoring policies
International Journal of Risk and Safety in Medicine 2002;15:(1-2):15-27
HSL7652
Vivian JC.
Federal limits on gifts from pharmaceutical companies
US Pharmacist 2002;27:(11):96-98,101
HSL7654
Adcock H.
Pharmageddon: is it too late to tackle growing resistance to anti-infectives?
Pharmaceutical Journal 2002;269:(7221):599-600
HSL7656
Goeschl T.
Stakes in the evolutionary race: The economic value of plants for medicinal applications
Journal of Herbs Spices and Medicinal Plants 2002;9:(4):373-388
HSL7657
Koch YD, Ernst ME, Kelly MW.
Patient perceptions about drug advertising and prescription-to-nonprescription switches
American Journal of Health System Pharmacy 2002;59:(16):1568
HSL7659
Drife J.
Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?
Drug Saf 2002;25:(13):893-902
HSL7661
Vidotti CC, Pereira DM, Marin NJ.
Drug nomenclature in Brazil: The official project "Harmonization of drug and excipients nomenclature for use in medicines"
International Pharmaceutical Federation World Congress 2002;62:(147):
HSL7663
Bessell TL, Silagy CA, Anderson JN, Hiller JE, Sansom LN.
Can we regulate e-pharmacies?
International Pharmaceutical Federation World Congress 2002;62:(68):
HSL7664
Subramaniam V, Schmid J.
Patient safety and regulatory initiatives through drug quality monitoring: Perspectives from the Food and Drug Administration
International Pharmaceutical Federation World Congress 2002;62:(9):
HSL7666
Griffenhagen G.
150 years of American pharmacy
International Pharmaceutical Federation World Congress 2002;62:(153):
HSL7668
Wogalter MS, Smith-jacksontl , Mills BJ, Paine CS.
The effects of print format in direct-to-consumer prescription drug advertisements on risk knowledge and preference
Drug Information Journal 2002;36:(3):693-705
HSL7670
Kiene B, Braun N, Freund M, Kliegl T.
Public advertising for prescription medicine
Deutsche Apotheker Zeitung 2002;142:(18):59-63
HSL7672
Sellers LJ.
Lilly marketers cross the line
Pharmaceutical Executive 2002;22:(9):20
HSL7676
Kiene B, Braun N, Freund M, Kliegel T.
Public advertising for prescription medication. Part 2. Different interests and solutions
Deutsche Apotheker Zeitung 2002;142:(19):47-50,55-57
HSL7677
Southern WA.
Sources of drug market data [1953].
Pharm Hist 2002;44:(2):77-82
HSL7679
Houlton S.
Drug info war heats up
Pharmaceutical Executive 2002;22:(8):30
HSL7730
Alonso J.
CRM - The 'ecosystem' difference
Pharmaceutical Executive 2002;22:(8):44,46,48,50,52
HSL7732
O'Hara P.
Policing CRM sampling
Pharmaceutical Executive 2002;22:(8):56,58,60,62-63,66
HSL7733
Wechsler J.
House adopts Medicare rx benefit
Pharmaceutical Executive 2002;22:(8):26,28
HSL7734
Buckley B.
Center saves millions via indigent care plans
Pharmacy Practice News 2002;29:(7):13, 51
HSL7735
Egler M, Geursen R.
Reference pricing: When hope triumphes over reality
Drugs Made in Germany 2002;45:(2):35-38,40-42
HSL7736
Koo M, Krass I, Aslani P.
Consumer opinions on medicines information and factors affecting its use - an Australian experience
International Journal of Pharmacy Practice 2002;10:(2):107-114
HSL7737
Drugs in 2001 - A number of ruses unveiled
Prescrire International 2002;11:(58):58-60
HSL7738
Boland KA, Kennedy AG, Possidente CJ.
Development of an annual program to discuss innovative pharmacy practices in Vermont
ASHP Midyear Clinical Meeting 2002;
HSL7739
Peters BN, Boster EA, Kroskie CA, Morvay SI, Zaucha JA.
Redesign of a pharmacy internship program
ASHP Midyear Clinical Meeting 2002;
HSL7740
Del PAGGIO.
Evaluation of atypical antipsychotic medication assistance programs in a county mental health system
ASHP Midyear Clinical Meeting 2002;
HSL7741
Daberko JD, Bays AM, Kier KL.
Evaluating web-based direct-to-consumer advertising
ASHP Midyear Clinical Meeting 2002;
HSL7742
Rosier RA, Phillips RE, Elam JW.
Medication assistance outpatient program; providing access to free or low cost pharmaceuticals.
ASHP Midyear Clinical Meeting 2002;
HSL7743
Aggarwal K, Cowley EP.
Beyond approved labeling: The USPDI medication information development process.
ASHP Midyear Clinical Meeting 2002;
HSL7744
Top 10 drugs of 2001
Pharmacy Times 2002;68:(4):10,12,15
HSL7745
Smith NV, Ramseyer KE.
Taking the package insert into the electronic age
Drug Information Journal 2002;36:(2):429-434
HSL7746
Kaupp GS, Lynch SB.
To regain control of their drug costs, health plans must understand the road they've traveled
Drug Benefit Trends 2002;14:(4):49-50
HSL7747
Advertised prescription drugs are the hot sellers
Drug Benefit Trends 2002;14:(4):4
HSL7748
Chumney EC, Simpson KN.
The emerging role of the consumer in pharmaceutical pricing decisions
Disease Management and Health Outcomes 2002;10:(4):229-232
HSL7749
Tieman J.
Drug-altered states - As pharmaceutical spending continues to soar, state legislatures are taking bold steps to rein in their costs
Modern Healthcare 2002;32:(17):28-31
HSL7750
Schobben AF, Rademaker CM.
Awakening attention for a particular target group. Drug registrations for children
Pharmaceutisch Weekblad 2002;137:(18):651-654
HSL7751
Milne CP.
The single controlled trial: Industry survey indicates that implementation is still a work in progress
Drug Information Journal 2002;36:(2):291-302
HSL7752
Saunders B, Farine A, Kellerman J.
Caught in the crosshairs - Pharmaceutical pricing and sales & marketing practices
Pharmaceutical Executive 2002;22:(4):50,52,54,56,58
HSL7753
Wechsler J.
Congress expands drug safety surveillance as part of bioterrorism bill
Formulary 2002;37:(7):368-369
HSL7754
Shalo S.
The cyber six: ePharma's hot growth spots
Pharmaceutical Executive 2002;22:(1):72-74,76,78
HSL7755
Nozar RA.
Education and promotion of generics might put the brakes on pharm costs
Managed Healthcare Executive 2002;12:(2):36, 38
HSL7756
Gebhart F.
Still growing - Steady, not stellar, growth marked the pharmaceutical market last year
Drug Topics 2002;146:(6):25-26,28,30
HSL7757
Wechsler J.
Price push forces plans to shift costs to consumers - MCOs implement multi-tier benefit to slow drug-spending growth, but future fiscal controls could limit access
Managed Healthcare Executive 2002;12:(1):32-33
HSL7760
Rybicki AL.
Pharmacists fill a prescription for good health
Michigan Pharmacist 2002;40:(1):38-39
HSL7761
Gebhart F.
Pharmacists welcome vouchers in place of drug samples
Drug Topics 2002;146:(2):25-26
HSL7766
Thornton RA, Hamilton S, Helmeczi AW.
Effective utilization of manufacturer's indigent medication reimbursement programs and patient financial screening to reduce financial losses in an ambulatory pharmacy setting.
ASHP Summer Meeting 2002;59:36
Page 158 of 206 pages ‹ First < 156 157 158 159 160 > Last ›
